Go Pro
→ Why I went to Mount Rushmore (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$5.32
$5.80
$1.74
▼
$6.60
$743.84M0.791.90 million shs3.28 million shs
Annexon, Inc. stock logo
ANNX
Annexon
$3.94
$5.26
$2.32
▼
$7.18
$746.95M1.212.54 million shs3.94 million shs
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
$5.38
$4.93
$2.86
▼
$16.34
$200.03M1.3477,984 shs43,604 shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$11.21
$12.07
$9.62
▼
$21.34
$793.44M0.0116,620 shs39,065 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
0.00%-13.78%-7.96%+22.02%+172.82%
Annexon, Inc. stock logo
ANNX
Annexon
0.00%-19.10%-25.52%-15.09%+62.81%
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
0.00%-7.88%+17.98%-22.14%+82.99%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.00%-0.18%-4.35%-12.49%-23.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$5.32
$5.80
$1.74
▼
$6.60
$743.84M0.791.90 million shs3.28 million shs
Annexon, Inc. stock logo
ANNX
Annexon
$3.94
$5.26
$2.32
▼
$7.18
$746.95M1.212.54 million shs3.94 million shs
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
$5.38
$4.93
$2.86
▼
$16.34
$200.03M1.3477,984 shs43,604 shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$11.21
$12.07
$9.62
▼
$21.34
$793.44M0.0116,620 shs39,065 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
0.00%-13.78%-7.96%+22.02%+172.82%
Annexon, Inc. stock logo
ANNX
Annexon
0.00%-19.10%-25.52%-15.09%+62.81%
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
0.00%-7.88%+17.98%-22.14%+82.99%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.00%-0.18%-4.35%-12.49%-23.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
3.11
Buy$11.33113.03% Upside
Annexon, Inc. stock logo
ANNX
Annexon
2.40
Hold$15.14284.34% Upside
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
2.67
Moderate Buy$15.00178.81% Upside
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.20
Hold$38.67244.93% Upside

Current Analyst Ratings Breakdown

Latest ARMP, ACRS, ANNX, and PHAR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/1/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$10.00
9/1/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$10.00
9/1/2026
Annexon, Inc. stock logo
ANNX
Annexon
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$10.00 ➝ $14.00
8/13/2026
Annexon, Inc. stock logo
ANNX
Annexon
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderperform ➝ Market Perform
8/7/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
8/3/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$37.00 ➝ $38.00
7/31/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/30/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
7/21/2026
Annexon, Inc. stock logo
ANNX
Annexon
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Underperform
7/21/2026
Annexon, Inc. stock logo
ANNX
Annexon
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Underperform$3.00
7/20/2026
Annexon, Inc. stock logo
ANNX
Annexon
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$14.00
(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$7.83M95.00N/AN/A$0.85 per share6.26
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/A$1.42 per shareN/A
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
$4.90M40.82N/AN/A($6.00) per share-0.90
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$376.13M2.11$0.20 per share55.90$3.95 per share2.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$64.92M-$0.58N/AN/AN/A-921.50%-61.65%-42.41%11/5/2026 (Estimated)
Annexon, Inc. stock logo
ANNX
Annexon
-$206.69M-$1.16N/AN/AN/AN/A-106.15%-79.82%11/9/2026 (Estimated)
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
-$173.80M-$1.64N/AN/AN/A-3,467.04%-12.24%32.16%11/11/2026 (Estimated)
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$2.85M$0.1293.4237.37N/A2.51%3.40%1.90%11/5/2026 (Estimated)

Latest ARMP, ACRS, ANNX, and PHAR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Annexon, Inc. stock logo
ANNX
Annexon
-$0.2388-$0.28-$0.0412-$0.28$6.50 millionN/A
8/12/2026Q2 2026
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
-$0.4450-$0.27+$0.1750-$0.27$0.40 million$2.51 million
8/6/2026Q2 2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.16-$0.15+$0.01-$0.15$1.38 million$1.63 million
7/30/2026Q2 2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$0.0630$0.02-$0.0430$0.02$99.52 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/AN/AN/AN/AN/A
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/AN/A
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
N/AN/AN/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/A
3.46
3.46
Annexon, Inc. stock logo
ANNX
Annexon
N/A
5.53
5.53
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
N/A
0.11
0.11
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.34
3.01
2.31

Institutional Ownership

CompanyInstitutional Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
98.34%
Annexon, Inc. stock logo
ANNX
Annexon
N/A
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
3.57%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.03%

Insider Ownership

CompanyInsider Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
4.80%
Annexon, Inc. stock logo
ANNX
Annexon
10.31%
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
84.50%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
73139.82 million133.11 millionOptionable
Annexon, Inc. stock logo
ANNX
Annexon
92189.58 million170.03 millionOptionable
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
7037.18 million5.76 millionNot Optionable
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
40770.78 million69.31 millionNot Optionable

Recent News About These Companies

Pharming Group Obtains US FDA Nod for Rare Primary Immunodeficiency Drug Joenja
 |  marketscreener.comM
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update
September 12 at 9:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-pharming-group-nv-sponsored-adr-nasdaq-phar-short-interest-update-2026-09-12/
Pharming Gets FDA Approval for Joenja to Treat APDS in Children Aged 4-11
September 11 at 6:01 PM  |  marketscreener.comM
Pharming Gets FDA Approval For Joenja In Children With APDS
September 11 at 6:01 PM  |  rttnews.comhttps://www.rttnews.com/3690452/pharming-gets-fda-approval-for-joenja-in-children-with-apds.aspx
FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.
September 11 at 6:01 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fda-approves-pharming-joenja-first-180000437.html
FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.
September 11 at 3:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/11/3360484/0/en/fda-approves-pharming-s-joenja-as-first-treatment-for-children-with-apds-in-the-u-s.html
Pharming Group (NASDAQ:PHAR) Shares Gap Down - Time to Sell?
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-pharming-group-nasdaq-phar-shares-gap-down-time-to-sell-2026-09-10/
Pharming: Faltering Rare-Disease Franchise With Two Potentially Transformative Late-Stage Assets
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944187-pharming-faltering-rare-disease-franchise-with-two-potentially-transformative-late-stage-assets
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Consensus Rating of "Hold" by Analysts
September 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31008881
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Consensus Recommendation of "Hold" by Brokerages
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-pharming-group-nv-sponsored-adr-nasdaq-phar-given-consensus-recommendation-of-hold-by-brokerages-2026-09-07/
Pharming Group (NASDAQ:PHAR) Shares Gap Up - Should You Buy?
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-pharming-group-nasdaq-phar-shares-gap-up-should-you-buy-2026-09-02/
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Increase in Short Interest
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-pharming-group-nv-sponsored-adr-nasdaq-phar-sees-large-increase-in-short-interest-2026-08-27/
Pharming Group (NASDAQ:PHAR) Shares Gap Up - What's Next?
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-pharming-group-nasdaq-phar-shares-gap-up-whats-next-2026-08-26/
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 93.0% in July
August 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pharming-group-nv-sponsored-adr-nasdaqphar-short-interest-up-930-in-july-2026-08-16/
Pharming introduces Joenja in Japan for adult and paediatric patients with activated PI3K delta syndrome aged 4 and older
August 14, 2026  |  pharmabiz.comP
Pharming Group N.V.: Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69299602-pharming-group-n-v-pharming-announces-commercial-launch-of-joenja-leniolisib-in-japan-for-adult-and-pediatric-patients-with-apds-aged-4-and-older-399.htm
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
August 13, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/pharming-announces-commercial-launch-of-joenja-leniolisib-in-japan-for-adult-and-pediatric-patients-with-apds-aged-4-and-older-1036452444
Pharming Group (PHAR) Stock Price, Quote, News & History
August 12, 2026  |  benzinga.comhttps://www.benzinga.com/quote/PHAR
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky
August 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/pharming-group-phar-securities-investigation-notice---levi--korsinsky-302845698.html
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
August 5, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/08/05/10426036.htm
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.
August 5, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260805570152/en/securities-fraud-investigation-into-pharming-group-n.v.-phar-announced-%e2%80%93-shareholders-who-lost-money-urged-to-contact-the-law-offices-of-frank-r.-cruz/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aclaris Therapeutics stock logo

Aclaris Therapeutics NASDAQ:ACRS

$5.32 0.00 (0.00%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$5.44 +0.11 (+2.16%)
As of 04:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Annexon stock logo

Annexon NASDAQ:ANNX

$3.94 0.00 (0.00%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$3.91 -0.03 (-0.76%)
As of 06:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Armata Pharmaceuticals stock logo

Armata Pharmaceuticals NYSEAMERICAN:ARMP

$5.38 0.00 (0.00%)
Closing price 09/11/2026 04:10 PM Eastern
Extended Trading
$5.40 +0.01 (+0.28%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$11.21 0.00 (0.00%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$11.05 -0.16 (-1.43%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas